X-imaging Secures Over RMB 100 Million Series B Funding to Accelerate AI-Driven Smart Laboratory Automation

VCBeat has learned that X-imaging recently announced the completion of its Series B financing round, exceeding RMB 100 million.This round of financing was led by Wisdomont Capital, a specialized biomedical investment institution, and followed by several Yangtze River Delta integration-focused investors, including industrial investor DNE CAPITAL, Aibo Qingshi Fund, and Wosheng Capital. WinX Capital served as the exclusive financial advisor for this financing round.

Following this round of financing, Huixiang Technology will further increase its investment in product R&D and market expansion, continuing to deepen its presence in life sciences, medical diagnostics, and inspection and testing. This will accelerate the promotion and implementation of Huixiang Technology’s AI-driven automation, AI robot scientists, and smart laboratory products and solutions.

The “Digital China” strategy proposed in China’s 14th Five-Year Plan explicitly identifies the intelligent and digital transformation of traditional laboratories as a key component. With the rapid advancement of artificial intelligence, automation, and robotics, the shift toward automated and intelligent operations in traditional laboratories across fields such as drug discovery, synthetic biology, and testing/inspection has become an irreversible trend. The integration of laboratory automation with AI has significantly enhanced scientists’ research efficiency and shortened the cycle for delivering scientific outcomes.

As an AI technology company focused on the scientific field, X-imaging is committed to advancing scientific research with AI technology.

Over the past few years, Huixiang has built an elite team comprising “application scientists + AI experts + automation experts + engineering experts,”Leveraging its “Four Major Technology Platforms”—the iMageOS intelligent operating system platform, the robotic automation technology platform, the AI big data intelligence platform, and the applied technology service platform—the company provides customers in the life sciences, pharmaceuticals, clinical diagnostics, and analytical testing industries with comprehensive solutions ranging from reagents and consumables, automated instruments and equipment, and automated production lines to smart laboratory overall solutions.To date, we have accumulated hundreds of client cases, covering many industry leaders, formed a stable ecosystem growth system with clients, and achieved breakthrough results in multiple fields.

Huixiang Technology for Life Sciences, Pharmaceuticals, Clinical Diagnostics, and Analytical Testing

Providing End-to-End Automated Solutions for Industry Clients

Designed specifically for laboratory applications, Huixiang Technology has newly launched the “Helen X” series of intelligent robots. Ranging from fixed five-axis arms to mobile seven-axis AGV robots, this series aims to provide collaborative robots highly tailored to laboratory needs, addressing challenges such as limited space, complex operations, and the need for flexible collaboration. It broadly covers diverse application scenarios in chemistry, analysis, testing, and biological research laboratories.

 Huixiang “Zhi Ling Zhe” Intelligent Robot Series

Huixiang Technology continues to strengthen its independent R&D of standalone equipment, developing multi-functional, multi-channel universal automated liquid handling systems tailored for automated applications in life sciences. These systems are efficient, user-friendly, and labor-saving, highly compatible with the integration of automated functional islands, and can flexibly replace certain imported equipment, thereby reducing costs.

Leveraging its technological expertise in intelligent control and smart imaging, Huixiang Technology has developed a microbiology technology platform that enables end-to-end automated experimental analysis, spanning from intelligent preparation and cultivation of microorganisms to intelligent analysis and screening of microbial colonies. The platform is widely applied in various microbiological testing and analysis scenarios, ranging from biomanufacturing and drug development to clinical diagnostics, and has been successfully implemented at renowned universities and food enterprises.

Leveraging AI-driven automation and digitalization, Huixiang has independently developed a multifunctional chemical liquid preparation workstation and an intelligent high-throughput solid-state screening workstation, with core modules including robotic arms, solid dispensing and weighing systems, and central control systems. These solutions significantly reduce costs associated with manual operational errors and enhance the accuracy of experimental processes, while also freeing up human resources and saving time on experiment preparation. The systems have been successfully deployed at a leading pharmaceutical company.

Huixiang Technology is one of the earliest enterprises to transform the concept of robotic scientists into commercial products. The Huixiang AI Robotic Scientist System, equipped with its independently developed ImageOS cloud-based intelligent system (comprising an intelligent operating system, a high-performance AI computing platform, and a distributed intelligent data center) and the Huixiang Intelligent Robot System, enables seamless collaboration with human scientists in scientific experiments, thereby achieving automation of scientific experiments, visualization of knowledge and data, and intelligent management of experimental processes.

Huixiang “Intelligent Experimenter” and “Intelligent Pathfinder” AI Robot Scientists

To address diverse analytical scenarios in the life sciences sector, Huixiang Technology has designed solutions such as intelligent NGS next-generation sequencing and library preparation automation systems, as well as intelligent hybridoma screening and detection automation systems, through modular hardware integration. Leveraging comprehensive interdisciplinary capabilities and supported by AI-driven decision-making platforms, the company has further developed a closed-loop “dry-wet” super smart laboratory, thereby achieving true end-to-end automation of life science laboratories.

 Huixiang Life Sciences: End-to-End Smart Laboratory

Huixiang Technology’s Smart Laboratory can integrate most mainstream laboratory equipment. Driven and managed by a data center, the entire laboratory facilitates an upgrade from single processes to single-island, multi-island, and multi-island interconnected super smart laboratories, covering everything from reagent and consumable storage to final data storage.

In the future, Huixiang Technology will be committed to bringing AI robotic scientists to every laboratory around the world, assisting human scientists in completing various scientific research tasks ranging from drug discovery and biomanufacturing to energy and chemical engineering, as well as disease diagnosis and treatment, thereby promoting the automation of scientific laboratories, the visualization of knowledge, and intelligent innovation.Empowering the development of global technology and science industries, leveraging technological advancements to realize the vision of “ensuring that everyone in the world enjoys a healthy, safe, and high-quality life.”

 Huixiang Technology's AI Robot Scientists Operate in Smart Laboratories

Dr. Liu Jiapeng, Founder and CEO of Huixiang Technology“The company’s continued receipt of trust and support from professional investment institutions, despite the challenging market environment, serves as a dual endorsement of Huixiang Technology’s existing achievements and future prospects. Following the completion of this financing round, the company will continue to adhere to its dual principles of ‘product focus’ and ‘customer-centricity,’ deeply cultivating the fields of laboratory automation and smart laboratories. Leveraging ‘AI + robotics’ as its core technology and building upon its portfolio of implemented case studies, Huixiang will drive development through a dual-core business model comprising ‘intelligent standardized products’ and ‘smart solutions.’ We firmly believe that the application of laboratory automation technologies and artificial intelligence (AI) will become a key driver for the industrial upgrading of scientific research.”

Dr. Cheng Hao, Partner at Wisdomont Capitalstated: “Under the leadership of its founder, Dr. Liu Jiapeng, Huixiang Technology has overcome numerous challenges and achieved rapid growth in recent years, gradually emerging as a leader in the life sciences automation industry. We are pleased to lead this round of financing and look forward to Dr. Liu continuing to guide his team in rising to challenges, navigating market cycles, and leveraging automation and artificial intelligence technologies to drive the upgrading of research in the biopharmaceutical and life health industries.”

Wang Zicong, Partner at Aibo Qingshi Fundstated: “Automation and intelligence in the life sciences sector are gaining significant momentum. The team at Huixiang Technology possesses interdisciplinary expertise in artificial intelligence and biopharmaceuticals, enabling it to provide comprehensive solutions encompassing hardware, software, and algorithms. These solutions help clients achieve data accumulation and enhanced operational efficiency, with their commercial capabilities already validated through successful deliveries to benchmark customers such as Insilico Medicine. Huixiang Technology’s integrated innovation business model boasts distinct platform advantages and first-mover advantages. We are confident that as more commercial projects are implemented, the company will further enhance the autonomy and standardization of its products, thereby strengthening its competitiveness and growth potential. Aibo Qingshi Fund will provide active support in business expansion and industrial implementation, helping Huixiang Technology achieve steady and long-term development, and contributing to the deepening automation and intelligence of the life sciences industry.”

Wang Yingpei, Co-Founder of DNE CAPITALIt stated: “As an emerging sector, the automation of scientific experiments boasts extensive downstream application scenarios, including drug R&D, testing and inspection, food and agriculture, and synthetic biology, indicating immense market potential. Dr. Liu’s multidisciplinary team has demonstrated pioneering spirit, establishing a leading industry position through star cases such as Insilico Medicine. We look forward to Huixiang Technology achieving continuous commercial breakthroughs in life sciences and other application fields. DNE CAPITAL is actively deploying in the life and health sector, having invested in multiple leaders across niche segments. Leveraging its unique industrial resources and ecosystem advantages, it assists enterprises in their development and expansion.”

Cao Zheng, Founding Partner of Wosheng Capitalstated, “We are firmly bullish on the trend of deep integration and cross-disciplinary convergence among life sciences, chemistry, and automation. As a leading enterprise in laboratory automation, Huixiang Technology has delivered reliable solutions to more than 100 life science and testing companies. We look forward to Dr. Liu leading the Huixiang team to continue empowering industrial upgrading in China’s life sciences, biochemical testing, and pharmaceutical research sectors.”

Zou Guowen, Founding Partner of WinX Capital“WinX Capital is honored to serve as the exclusive financial advisor for Huixiang Technology’s Series B financing round. Scientific experimentation is undergoing a transformation from manual to automated, and from automated to intelligent processes, with the laboratory automation sector experiencing rapid growth. Huixiang Technology provides end-to-end automated and intelligent solutions for clients across biochemistry, healthcare, pharmaceuticals, and testing/inspection sectors, having accumulated numerous high-quality benchmark customers. We are fully confident that Huixiang Technology will become a leading enterprise in the field of laboratory automation.”

Huixiang Technology is an AI technology company focused on the scientific field, dedicated to advancing scientific research through AI technologies. It provides end-to-end automated systems and solutions for the life sciences, pharmaceuticals, clinical diagnostics, and analytical testing industries, and is one of the earliest companies to transform the concept of robot scientists into commercial products.

Wisdomont Capital, established in 2014, specializes in equity investments in the life sciences and healthcare sectors. The company’s founder and investment research team possess extensive expertise in medical professions, industry backgrounds, and capital operations. Adhering to the principles of “technology-driven, clinical-oriented, industry-integrated, and value-based investing,” Wisdomont Capital deeply focuses on leading enterprises in niche segments such as biotechnology, innovative drugs, and digital healthcare, serving as a long-term enabler for these companies. Portfolio companies include Cambridge Industries Group (603083.SH), OLED Material Tech (688378.SH), Viva Biotech (01873.HK), Sun-Novo Pharmaceutical Research (688621.SH), Obio Technology (688238.SH), Kangfeng Biotherapeutics (6922.HK), USChina Cancer Care, Yikon Genomics, GenePlus Technologies, Ascentage Pharma, StarMed Medical, Jiangfeng Biology, PinFeng Medical, QinHao Medicine, and Changjin Biologics.

Aibo Qingshi Fund is an industrial fund established through a collaboration between Aibo Medical (688050.SH) and Qingshi Asset Management Group, focusing on investments in the innovative medical device sector. Representative portfolio companies include Tiluo Medical, Tupai Medical, Pinchi Medical, Huakan Bio, Aoda Zhisheng, and Konuomei.

Leveraging the infrastructure network of Dongjiu Xinyi Group, we prioritize strategic emerging industries—including biopharmaceuticals and healthcare, next-generation information technology, new energy, artificial intelligence, advanced manufacturing, new materials, and green low-carbon environmental protection. By adopting a diversified operational model of “direct investment + funds + enterprise incubation,” we aim to build a closed-loop ecosystem spanning the entire industry chain.

Wosheng Capital, established in 2016, is a mature and stable investment team focused on the healthcare industry, committed to becoming a research-oriented integrator of healthcare industry resources. Since its inception, Wosheng has invested in 27 innovative enterprises with high growth potential within the healthcare sector.

WinX Capital is a leading investment bank in China’s healthcare sector, headquartered in Beijing and Shanghai, with coverage of over 3,000 active institutional investors and industrial groups. It has received numerous accolades, including “No. 1 Financial Advisor in Healthcare for 2022” by First New Voice, “Top 2 Best Financial Advisors in Healthcare for 2021–2022” by Qimingpian & New Voice Innovation Services, and “Top 5 Healthcare Financial Advisor of the Year at the 2022–2023 Pengcheng Awards” by VCBeat.